184 related articles for article (PubMed ID: 31769845)
1. Low-dose corticosteroid and mycophenolate for primary treatment of minimal change disease.
Ma MKM; Yap DYH; Li CL; Mok MMY; Chan GCW; Kwan LPY; Lai KN; Tang SCW
QJM; 2020 Jun; 113(6):399-403. PubMed ID: 31769845
[TBL] [Abstract][Full Text] [Related]
2. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).
Rémy P; Audard V; Natella PA; Pelle G; Dussol B; Leray-Moragues H; Vigneau C; Bouachi K; Dantal J; Vrigneaud L; Karras A; Pourcine F; Gatault P; Grimbert P; Ait Sahlia N; Moktefi A; Daugas E; Rigothier C; Bastuji-Garin S; Sahali D;
Kidney Int; 2018 Dec; 94(6):1217-1226. PubMed ID: 30385039
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with
Medjeral-Thomas NR; Lawrence C; Condon M; Sood B; Warwicker P; Brown H; Pattison J; Bhandari S; Barratt J; Turner N; Cook HT; Levy JB; Lightstone L; Pusey C; Galliford J; Cairns TD; Griffith M
Clin J Am Soc Nephrol; 2020 Feb; 15(2):209-218. PubMed ID: 31953303
[TBL] [Abstract][Full Text] [Related]
4. Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.
Shirai S; Imai N; Sueki S; Matsui K; Tominaga N; Sakurada T; Yasuda T; Kimura K; Shibagaki Y
Clin Exp Nephrol; 2018 Apr; 22(2):283-290. PubMed ID: 28699032
[TBL] [Abstract][Full Text] [Related]
5. The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease.
Siu YP; Tong MK; Leung Ka; Kwan TH; Au TC
J Nephrol; 2008; 21(1):127-31. PubMed ID: 18264946
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial.
Deuter CME; Engelmann K; Heiligenhaus A; Lanzl I; Mackensen F; Ness T; Pleyer U; Stuebiger N; Wilhelm B; Luedtke H; Zierhut M; Doycheva D;
Br J Ophthalmol; 2018 May; 102(5):647-653. PubMed ID: 28903965
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.
Shinzawa M; Yamamoto R; Nagasawa Y; Oseto S; Mori D; Tomida K; Hayashi T; Izumi M; Fukunaga M; Yamauchi A; Tsubakihara Y; Isaka Y
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1040-8. PubMed ID: 24721890
[TBL] [Abstract][Full Text] [Related]
9. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.
Chin HJ; Chae DW; Kim YC; An WS; Ihm C; Jin DC; Kim SG; Kim YL; Kim YS; Kim YG; Koo HS; Lee JE; Lee KW; Oh J; Park JH; Jiang H; Lee H; Lee SK
J Am Soc Nephrol; 2021 Jan; 32(1):199-210. PubMed ID: 33168602
[TBL] [Abstract][Full Text] [Related]
11. [Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy].
Hayashi M; Kimura N; Fukatsu A
Nihon Jinzo Gakkai Shi; 2008; 50(5):581-7. PubMed ID: 18767486
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults.
Fujiwara A; Hirawa N; Kobayashi Y; Yatsu K; Katsumata M; Ehara Y; Okuyama Y; Yutoh J; Kaneda T; Fujita M; Yamamoto Y; Saka S; Toya Y; Yasuda G; Umemura S
Clin Exp Nephrol; 2015 Apr; 19(2):240-6. PubMed ID: 24771147
[TBL] [Abstract][Full Text] [Related]
14. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.
Eguchi A; Takei T; Yoshida T; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2010 Jan; 25(1):124-9. PubMed ID: 19740915
[TBL] [Abstract][Full Text] [Related]
15. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
[TBL] [Abstract][Full Text] [Related]
16. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
18. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
[TBL] [Abstract][Full Text] [Related]
19. [Mycophenolate mofetil for induction of remission in Wegener's granulomatosis].
Kötter I
Z Rheumatol; 2007 Sep; 66(5):441-3. PubMed ID: 17717676
[No Abstract] [Full Text] [Related]
20. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
